3SBio Inc. (TRSBF)

OTCMKTS · Delayed Price · Currency is USD
0.828
0.00 (0.00%)
Feb 27, 2025, 3:00 PM EST
3.49%
Market Cap 2.74B
Revenue (ttm) 1.16B
Net Income (ttm) 228.24M
Shares Out n/a
EPS (ttm) 0.09
PE Ratio 11.99
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 313
Average Volume n/a
Open 0.828
Previous Close 0.828
Day's Range 0.828 - 0.828
52-Week Range 0.723 - 0.828
Beta 0.71
RSI 99.73
Earnings Date Mar 21, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 5,411
Stock Exchange OTCMKTS
Ticker Symbol TRSBF
Full Company Profile

Financial Performance

In 2023, 3SBio's revenue was 7.82 billion, an increase of 13.84% compared to the previous year's 6.87 billion. Earnings were 1.55 billion, a decrease of -19.13%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.